|2.06||+0.0050||+0.24%||Vol 526.90K||1Y Perf -76.60%|
|Oct 4th, 2023 15:52 DELAYED|
|- -%||- -|
|Target Price||26.25||Analyst Rating||Strong Buy 1.00|
|Potential %||1.16K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-79/-93||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-82/-97||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-87/-94||Income Ranking||— -|
|Price Range Ratio 52W %||1.85||Earnings Rating||—|
|Market Cap||234.00M||Earnings Date||2nd Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2023|
|Estimated EPS Next Report||-0.42|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||635.93K|
|Avg. Monthly Volume||1.01M|
|Avg. Quarterly Volume||823.81K|
AlloVir Inc. (NASDAQ: ALVR) stock closed at 2.05 per share at the end of the most recent trading day (a 3.02% change compared to the prior day closing price) with a volume of 643.81K shares and market capitalization of 234.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. AlloVir Inc. CEO is David Hallal.
The one-year performance of AlloVir Inc. stock is -76.6%, while year-to-date (YTD) performance is -60.04%. ALVR stock has a five-year performance of %. Its 52-week range is between 1.9 and 10.29, which gives ALVR stock a 52-week price range ratio of 1.85%
AlloVir Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 1.89, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -61.79%, a ROC of -65.96% and a ROE of -72.43%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from AlloVir Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. AlloVir Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for AlloVir Inc. is Strong Buy (1), with a target price of $26.25, which is +1 162.02% compared to the current price. The earnings rating for AlloVir Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AlloVir Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AlloVir Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.21, ATR14 : 0.23, CCI20 : -101.74, Chaikin Money Flow : -0.05, MACD : -0.24, Money Flow Index : 40.46, ROC : -18.33, RSI : 34.00, STOCH (14,3) : 17.44, STOCH RSI : 0.33, UO : 41.99, Williams %R : -82.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AlloVir Inc. in the last 12-months were: Brainard Diana (Sold 81 534 shares of value $344 668 ), Brett R. Hagen (Sold 40 616 shares of value $325 910 ), Diana Brainard (Sold 44 072 shares of value $241 596 ), Diana M. Brainard (Sold 52 480 shares of value $272 779 ), Edward Miller (Sold 6 037 shares of value $44 472 ), Ercem Atillasoy (Sold 4 190 shares of value $36 545 ), GILEAD SCIENCES, INC. (Buy at a value of $10 990 762), Hagen Brett (Sold 7 637 shares of value $40 659 ), Hagen Brett R (Sold 5 729 shares of value $30 816 ), Jeroen B. Van Beek (Sold 68 214 shares of value $547 757 ), Sciences Inc Gilead (Buy at a value of $10 990 762), Sinha Vikas (Sold 5 618 shares of value $18 161 ), Vikas Sinha (Sold 32 069 shares of value $156 947 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.